.png)
Kindos operates highly efficient collaborative sites across US, China and EU. We have established a full industrial chain capability from clinical research to market sales in US and China, and have implemented globally integrated commercial collaborations in regulated markets.
Kindos provides a comprehensive CRDMO service that meets global regulatory market requirements. This includes high-standard R&D for the entire industry chain, covering small molecule sterile injections and biopharmaceuticals, as well as global filing and commercialization. Our one-stop service supports both domestic and international clients in accelerating development in the innovation sector while ensuring the continuous provision of high-quality medications for patients with critical diseases.
Kindos has professional regulatory registration teams in both US and China, with extensive experiences in FDA registration submissions, EMA (Centralized and Decentralized Procedures) registration and submission, US-China dual submissions, and synchronized launches in US, China and EU. We are capable of carrying out integrated, comprehensive global regulatory market registration submissions.
Since 2013, Kindos has directly marketed our self-developed and manufactured sterile injectable products for treating critical diseases in the US. In 2021, Kindos started product launch in China, playing an active role in the clinical treatment of critical diseases in China. We specialize in the research and commercialization of small molecule chemical drugs, antibody drugs, novel drug delivery systems, nucleic acid-based macromolecular biopharmaceuticals and novel vaccines. Kindos has independently developed products cover major therapeutic fields, including oncology, infectious diseases, cardiovascular conditions and autoimmune disorders, with simultaneous market launches in both US and China.